Form 4: Orchestra BioMed Holdings Director Mack John Prosper Reports Acquisition of Restricted Stock Units and Stock Options

Director Mack John Prosper reports the acquisition of restricted stock units and stock options in Orchestra BioMed Holdings, Inc.

Summary

• On August 7, 2024, Mack John Prosper, a director of Orchestra BioMed Holdings, Inc., reported the acquisition of 12,864 restricted stock units (RSUs) and 40,737 stock options.
• The RSUs were awarded to the Reporting Person on August 7, 2024.
• 6,003 RSUs vest on June 20, 2025, and the remaining 6,861 RSUs vest in three equal, annual installments beginning on August 7, 2025, contingent upon continuous service.
• The stock options have an exercise price of $5.83.
• 19,218 stock options vest on June 20, 2025, and the remaining 21,519 stock options vest in three equal, annual installments beginning on August 7, 2025, contingent upon continuous service.
• The stock options expire on August 7, 2034.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The granting of RSUs and stock options to a director is a common practice and suggests confidence in the company's future. However, it's a routine filing and doesn't necessarily indicate a major positive development.

Positives

• The acquisition of RSUs and stock options by a director signals confidence in the company's future performance.
• The vesting schedules incentivize long-term commitment and performance from the director.

Industry Context

This is a standard SEC Form 4 filing, reflecting changes in beneficial ownership by a company insider. Such filings are common and provide transparency to the market regarding insider transactions.

Stakeholder Impact

• Shareholders may view the granting of RSUs and stock options as a positive sign, aligning management's interests with theirs.
• Employees may see this as a sign of stability and investment in leadership.

Key Dates